0 19

Cited 0 times in

Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study

Authors
 Soo-Mee Bang  ;  Jin-Hyoung Kang  ;  Min Hee Hong  ;  Jin-Seok Ahn  ;  So Yeon Oh  ;  Jin Ho Baek  ;  Yoon Ji Choi  ;  Seong Hoon Shin  ;  Young-Joo Kim  ;  Ha-Yeong Gil  ;  Hyung-Eun Park  ;  Juneyoung Lee  ;  Eun-Lyeong Park 
Citation
 CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, Vol.27 : 1076029620979575, 2021-01 
Journal Title
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
ISSN
 1076-0296 
Issue Date
2021-01
MeSH
Administration, Oral ; Aged ; Anticoagulants / administration & dosage ; Anticoagulants / adverse effects ; Anticoagulants / therapeutic use ; Cohort Studies ; Female ; Hemorrhage / etiology ; Heparin, Low-Molecular-Weight / therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasms / complications* ; Pulmonary Embolism / drug therapy ; Pulmonary Embolism / etiology ; Recurrence ; Republic of Korea ; Retrospective Studies ; Risk Factors ; Treatment Outcome ; Venous Thromboembolism / drug therapy* ; Venous Thromboembolism / etiology*
Keywords
cancer ; direct oral anticoagulants ; low-molecular-weight heparin ; venous thromboembolism
Abstract
This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with cancer-associated VTE, and assessed factors associated with clinical outcomes. Data were extracted from retrospective medical-chart review of adult patients diagnosed with cancer-associated deep vein thrombosis or pulmonary embolism who received anticoagulation treatment for ≥3 months. Patients were classified by: low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and other anticoagulants. First VTE recurrence and bleeding events, and factors associated with their occurrence, were assessed during the initial 6 months of treatment. Overall, 623 patients (age: 63.7 ± 11.3 years, 49.3% male) were included (119, 132, and 372 patients in LMWH, DOACs and other anticoagulants groups, respectively). The cumulative 6-month incidence of VTE recurrence was 16.6% (total), 8.3% (LMWH), 16.7% (DOACs), and 20.7% (other); respective bleeding events were 22.5%, 11.0%, 12.3%, and 30.7%). VTE recurrence and bleeding rates differed only between LMWH and other anticoagulants (HR 2.4, 95% CI: 1.2-5.0 and 3.6, 1.9-6.8, respectively). These results highlight the importance of initial VTE treatment choice for preventing VTE recurrence and bleeding events. LMWH or DOACs for ≥3 months can be considered for effective VTE management in cancer patients.
DOI
10.1177/1076029620979575
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Hong, Min Hee(홍민희) ORCID logo https://orcid.org/0000-0003-3490-2195
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/185383
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links